MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Go back to MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
(NASDAQ: INKT) Delayed: 11.45 -0.19 (1.63%)
Previous Close $11.64    52 Week High
Open $11.61    52 Week Low
Day High $11.85    P/E N/A 
Day Low $11.45    EPS
Volume 11,019